U.S. markets close in 2 hours 6 minutes

CASI Pharmaceuticals, Inc. (CASI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5000-0.0100 (-0.66%)
As of 1:52PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close1.5100
Open1.4900
Bid1.5000 x 1200
Ask1.5100 x 800
Day's Range1.4900 - 1.5350
52 Week Range1.1500 - 3.6700
Volume54,702
Avg. Volume507,721
Market Cap185.916M
Beta (5Y Monthly)0.75
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • The CASI Pharmaceuticals (NASDAQ:CASI) Share Price Is Up 53% And Shareholders Are Holding On
    Simply Wall St.

    The CASI Pharmaceuticals (NASDAQ:CASI) Share Price Is Up 53% And Shareholders Are Holding On

    Some CASI Pharmaceuticals, Inc. (NASDAQ:CASI) shareholders are probably rather concerned to see the share price fall...

  • Zacks Small Cap Research

    CASI: A Change in Strategy

    By Beth Senko, CFA NASDAQ:CASI READ THE FULL CASI RESEARCH REPORT CASI Pharmaceuticals (NASDAQ:CASI) signaled a shift in its business strategy in March – focusing its efforts on its hematology franchise and deemphasizing its ANDA portfolio. This change scales back CASI’s initial broad-reaching goal to be the leading provider of high quality proprietary, licensed and ANDA pharmaceuticals to the

  • CASI Pharmaceuticals Inc (CASI) Q2 2020 Earnings Call Transcript
    Motley Fool

    CASI Pharmaceuticals Inc (CASI) Q2 2020 Earnings Call Transcript

    Earlier today, CASI issued a press release providing the details of our financial results for the quarter ended June 30, 2020, as well as a corporate and clinical update. The press release is available in the Investor Relations section of our website at casipharmaceuticals.com.